Omega-3 fatty acids

Omega-3 fatty acids has been studied in 899 papers since 1987: 298 trials and 109 observational studies in people, 30 in animals, 445 reviews; 218 in the past year. The newest story, Nov 14, 2026: “Omega-3s did not significantly cut major cardiovascular events”.

Intervention

899 papers study it645 findingsUpdated

Research on it is growing 50% faster than aging research as a whole: 36 papers in the latest year counted

Part of Bryan Johnson's Blueprint and Rhonda Patrick's supplement routineMore supplements

24 new papers in 30 daysSee all 731 papers on omega-3 fatty acids

At a glance

A human trial reports lower mortality with omega-3 fatty acids; another reports lower aging-clock measures, but trials show no clear effect on frailty or cognition. Independent labs reproduce triglyceride reductions in humans and inflammation reductions in mice. Developers sponsor most trials; 10 concern aging, and across all uses, two ended over a year ago without posted results or citing papers.

645 findings in 326 papers from 1987 to 2026, 32 of them since April 2026

Independent labs found the same change in mice and people. 181 independent labs in 37 countries; 22 trials, 11 about aging, 3 with no results posted.

“the n-3 FA supplement did not significantly reduce the primary endpoint of major CVD events”
Omega-3 Fatty Acid Supplementation Has Coronary and Other Selective Health Benefits: Comprehensive Results from the VITamin D and OmegA-3 TriaL (VITAL)The Journal of nutrition2026doi:10.1016/j.tjnut.2026.101941

73 of its findings point the other way.

Mice and humans: replicated by independent labs. Cells: a single group. Worms or flies: nothing yet.
  • 181 independent labs in 37 countries
  • 73 findings against
  • 22 trials, 11 about aging, 3 with no results posted
  • Funders: National Institutes of Health and others
  • 59 of 548 findings with company ties
  • 14 of 22 trials sponsored by its developers
  • Human trial190
  • Humans108
  • Animals29
  • Model organisms1
  • In silico7

108 studies gave omega-3 fatty acids to people and measured what changed.

What changedDesignPeopleSource

no change: Has no effect on major cardiovascular eventsHR 0.92, 95% CI 0.80–1.06

down: Lowers the risk of myocardial infarctionHR 0.72, 95% CI 0.59–0.90

down: Decreases recurrent hospitalization for heart failureHR 0.86, 95% CI 0.74–0.998

Randomized trialmedian of 5.3 years25,871 peopleBothmen aged ≥50 and women aged ≥55 yearsMidlife adults; Older adults; General population; primary preventionThe Journal of nutrition, Nov 14, 2026

down: Decreases neutrophil-to-lymphocyte ratio−0.43; 95% CI −0.73 to −0.13

down: Decreases daytime systolic blood pressure−6.52 mmHg; 95% CI −10.66 to −2.39

down: Decreases estimated pulse wave velocity−0.77 m/s; 95% CI −1.19 to −0.36

Randomized trial12 weeks100 peopleadultsTreated hypertension and dyslipidemiaNutrients, Nov 9, 2026

up: Improves cognitive functionΔ ≈ +4.2 points

Trial12 weeks14 peopleolder adultsOlder adultsNutrición clínica y dietética hospitalaria/Nutrición clínica, dietética hospitalaria, Jun 30, 2026

no change: Has no effect on muscle massp = 0.300

no change: Has no effect on handgrip strengthall p ≥ 0.364

Randomized trial90 days58 peopleBothmean age 38.2 ± 9.9 yearsPerioperative period of bariatric surgeryJournal of cachexia, sarcopenia and muscle, Jun 1, 2026

down: Decreases Firmicutes/Bacteroidetes ratio

up: Increases propionate

down: Decreases butyrate

Randomized trial34 peopleWomenPostmenopausal women; among participants who lost ≥10% of their weightCancer prevention research (Philadelphia, Pa.), Apr 19, 2026

What did studies of omega-3 fatty acids find?

303

Studies of omega-3 fatty acids measured 303 outcomes; the most studied are triglyceride (22 studies), inflammation (21) and cognitive function (20).

Triglyceride

downin humans21downin reviews1−24%

22 studies
  1. Omega-3 fatty acids decrease triglyceride in humans.

    “n-3 PUFAs reduced total triglycerides, maintained HDL, reduced systolic blood pressure”

    Human trialethyl esters3.9 g/d6 mo

    A Randomized Trial of ω-3 Fatty Acid Supplementation and Circulating Lipoprotein Subclasses in Healthy Older Adults

    The Journal of nutrition

  2. Omega-3 fatty acids decrease triglyceride in humans (added to statin therapy versus statin alone).

    “Significant reduction of hepatic enzymes activity, systolic blood preasure, inflammatory markers and TAG levels were detected in both groups in comparison to the control group.”

    Human trialadded to statin therapy versus statin alone2.52 g/day3 months

    Addition of omega-3 fatty acid and coenzyme Q10 to statin therapy in patients with combined dyslipidemia

    Journal of basic and clinical physiology and pharmacology

  3. Omega-3 fatty acids decrease triglyceride in humans (obesity).

    “significantly decreased the concentrations of several inflammatory markers (SELE, MCP-1, sVCAM-1, sPECAM-1, and hsCRP), fasting triglycerides and insulin”

    Human trialobesityplasma1.8g EPA+DHA per day3 monthsfemales

    Omega-3 fatty acid supplementation influences the whole blood transcriptome in women with obesity, associated with pro-resolving lipid mediator production

    Biochimica et biophysica acta

  4. Omega-3 fatty acids decrease triglyceride in humans with caloric restriction.

    “This effect was greater and more significant in subjects also supplemented with n-3 PUFA (CR + n-3 group) whose decrease in fasting TG concentration and TG AUC during OGTT was approximately 30% below baseline (P = 0.0003).”

    Human trialwith caloric restriction3 monthsn = 48

    Effect of caloric restriction with or without n-3 polyunsaturated fatty acids on insulin sensitivity in obese subjects: A randomized placebo controlled trial

    BBA clinical

  5. Omega-3 fatty acids decrease triglyceride in humans.

    “The n-3 PUFA supplementation had an independent effect on plasma TG levels.”

    Human trial3 g/day6 weeksn = 208

    Association between polymorphisms in phospholipase A2 genes and the plasma triglyceride response to an n-3 PUFA supplementation: a clinical trial

    Lipids in health and disease

  6. Omega-3 fatty acids decrease triglyceride in humans.

    “The n-3 supplementation had an independent effect on plasma TG levels”

    Human trialplasma3 g/daysix weeksn = 208

    Association between polymorphisms in the fatty acid desaturase gene cluster and the plasma triacylglycerol response to an n-3 PUFA supplementation

    Nutrients

  7. Omega-3 fatty acids decrease triglyceride in humans (-0.41, 95% CI -0.69 to -0.13).

    “we observed significant reductions in TG for the N3 (- 0.41, 95 %CI, - 0.69, - 0.13) and MVit + N3 (- 0.71, 95 %CI, - 0.93, - 0.46) groups”

    Human trial12 weeksn = 100

    Complementary effects of multivitamin and omega-3 fatty acid supplementation on indices of cardiovascular health in individuals with elevated homocysteine

    International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition

  8. Omega-3 fatty acids decrease triglyceride in humans (nondiabetic chronic kidney disease stages 3-4) (-24%).

    “omega3FA reduced triglycerides 24% (P<0.001).”

    Human trialnondiabetic chronic kidney disease stages 3-44 g daily8 weeksn = 74

    The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial

    Journal of hypertension

  9. Omega-3 fatty acids decrease triglyceride in women with PCOS (1.19 (1.03-1.47) vs. 1.02 (0.93-1.18) mmol/liter, P = 0.002).

    “There was also a reduction in triglycerides [1.19 (1.03-1.47) vs. 1.02 (0.93-1.18) mmol/liter; P = 0.002]”

    Human trialin women with PCOS4g/d8 wkfemalesn = 25

    Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy

    The Journal of clinical endocrinology and metabolism

  10. Omega-3 fatty acids decrease triglyceride in humans (HIV-infected patients on HAART) (-2.32 mm (95% CI -4.52, -0.12 mm)).

    “The estimated difference between groups for change in mean triglycerides over 8 weeks was -2.32 mm (95% CI -4.52, -0.12 mm).”

    Human trialHIV-infected patients on HAARTsupplementation9 g8-weekmalesn = 11

    A randomised controlled trial of omega-3 fatty acid supplementation for the treatment of hypertriglyceridemia in HIV-infected males on highly active antiretroviral therapy

    Sexual health

All 22

More on Triglyceride

Inflammation

downin humans12downin reviews4no changein humans2downin mice2+1

21 studies
  1. Omega-3 fatty acids decrease inflammation in humans (combined with resistance training).

    “For CRP measurements, the group effect was p > 0.055, the effect of the time factor was p < 0.002, and the effect of the group × time interaction was p > 0.122.”

    Human trialcombined with resistance trainingeight consecutive weeksmalesn = 30

    The Effects of Omega-3 Supplementation Combined with Strength Training on Neuro-Biomarkers, Inflammatory and Antioxidant Responses, and the Lipid Profile in Physically Healthy Adults

    Nutrients

  2. Omega-3 fatty acids decrease inflammation in humans.

    “reductions in proinflammatory mediators, PGD2, 5-HETE, and 12-HETE”

    Human trial460 mg EPA + 380 mg DHA/dplasma1 year

    Joint effects of one year of marine omega-3 fatty acid supplementation and participant dietary fish intake upon circulating lipid mediators of inflammation resolution in a randomized controlled trial

    Nutrition (Burbank, Los Angeles County, Calif.)

  3. Omega-3 fatty acids decrease inflammation in combination with vibration and resistance exercise.

    “There was a trend, although non-significant, towards decreased IL-6 and IL-10 concentrations in the high-protein, omega-3-enriched group compared to control.”

    Human trialin combination with vibration and resistance exerciseeight weeksn = 61

    Effects of an Omega-3 Supplemented, High-Protein Diet in Combination with Vibration and Resistance Exercise on Muscle Power and Inflammation in Old Adults: A Pilot Randomized Controlled Trial

    Nutrients

  4. Omega-3 fatty acids inhibit inflammation in patients with lung cancer.

    “suppress the systemic inflammatory response in patients with lung cancer.”

    Human trialin patients with lung cancer12 weeksn = 60

    Omega-3 Fatty Acids Supplementation Improve Nutritional Status and Inflammatory Response in Patients With Lung Cancer: A Randomized Clinical Trial

    Frontiers in nutrition

  5. Omega-3 fatty acids showed no clear effect on inflammation in humans (muscle and blood markers) (+13% in PLAC and −52% in ω-3).

    “NF-κB (pltime =.60; plinteraction =.47), TNFα (pltime =.75; plinteraction =.37), and IL-1β (pltime =.68; plinteraction =.46) gene expression remained unchanged.”

    Human trialmuscle and blood markers14 weeksn = 23

    Omega-3 Supplementation Improves Isometric Strength But Not Muscle Anabolic and Catabolic Signaling in Response to Resistance Exercise in Healthy Older Adults

    The journals of gerontology. Series A, Biological sciences and medical sciences

  6. Omega-3 fatty acids decrease inflammation in humans (P < 0.001).

    “The concentrations of IFN-γ and IL-17 were significantly decreased in ω3FA group compared with the placebo group (P < 0.001).”

    Human trial60 daysmalesn = 53

    Omega 3 Supplementation Can Regulate Inflammatory States in Gas Station Workers: A Double-Blind Placebo-Controlled Clinical Trial

    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research

  7. Omega-3 fatty acids showed no clear effect on inflammation in insulin-resistant adults.

    “there were no significant changes in the IC50(palmitate)f (19 ± 2 compared with 24 ± 3 μIU/mL), adipose macrophages”

    Human trialin insulin-resistant adultsadipose tissue3.9 g/d (4.2 g total omega-3/d)6 mo

    Very-long-chain ω-3 fatty acid supplements and adipose tissue functions: a randomized controlled trial

    The American journal of clinical nutrition

  8. Omega-3 fatty acids decrease inflammation in humans (obesity).

    “n-3 PUFA supplementation, in contrast to placebo, significantly decreased the concentrations of several inflammatory markers (SELE, MCP-1, sVCAM-1, sPECAM-1, and hsCRP)”

    Human trialobesityplasma1.8g EPA+DHA per day3 monthsfemales

    Omega-3 fatty acid supplementation influences the whole blood transcriptome in women with obesity, associated with pro-resolving lipid mediator production

    Biochimica et biophysica acta

  9. Omega-3 fatty acids decrease inflammation in humans.

    “decreased systemic inflammation”

    Review

    Fortification of Omega-3 Fatty Acids in Food Products: Advancements, Methods, Benefits, and Consumer Acceptance - A Comprehensive Review

    International Journal for Research in Applied Science and Engineering Technology

  10. Omega-3 fatty acids decrease inflammation.

    “omega-3 supplementation may reduce inflammation”

    Review

    Anti-inflammatory effects of omega-3 fatty acids: Evidence from circulating biomarkers and inflammatory gene-expression studies

    African Research Reports

All 21

More on Inflammation

Cognitive function

upin humans12no changein humans6upin mice2downin humans1+1+44% rcts

20 studies
  1. Omega-3 fatty acids improve cognitive function in humans (Δ ≈ +4.2 points).

    “Both groups showed statistically significant improvements in global cognitive scores on the Addenbrooke’s Cognitive Examination (ACE) (Δ ≈ +4.2 points)”

    Human trial12 weeksn = 14

    Comparative Effects of Omega-3 and Creatine Supplementation on Cognitive Function and Body Composition in Older Adults: A Quasi-Experimental Study

    Nutrición clínica y dietética hospitalaria/Nutrición clínica, dietética hospitalaria

  2. Omega-3 fatty acids showed no clear effect on cognitive function in humans (individuals with raised baseline p-tau181, 12.4 pg/mL cutoff) (0.03 (95% CI -0.30 to 0.36)).

    “mean difference [95% CI] in this subgroup in 3-year decline on the composite cognitive score between the control group and the multidomain + omega-3 group, the omega-3 group, and the multidomain intervention group, was, respectively: 0·13 [-0·21 to 0·47], 0·03 [-0·30 to 0·36]”

    Human trialindividuals with raised baseline p-tau181, 12.4 pg/mL cutoff3-yearn = 527

    Plasma p-tau181 as an outcome and predictor of multidomain intervention effects: a secondary analysis of a randomised, controlled, dementia prevention trial

    The lancet. Healthy longevity

  3. Omega-3 fatty acids showed no clear effect on cognitive function in humans (overweight or obese adults on a weight loss diet).

    “MoCA scores increased in both groups within time, without statistical significance between groups.”

    Human trialoverweight or obese adults on a weight loss diet1020 mg daily12 weeksn = 40

    The effect of omega-3 fatty acid supplementation on weight loss and cognitive function in overweight or obese individuals on weight-loss diet

    Nutricion hospitalaria

  4. Omega-3 fatty acids showed no clear effect on cognitive function in humans (–0.01 (95% CI: –0.02, 0.003; P =.15)).

    “There were no significant effects of n‐3 supplementation on the primary outcome of change over time in the global composite score.”

    Human trial2 to 3 years

    Marine n-3 fatty acids and cognitive change among older adults in the VITAL randomized trial

    Alzheimer's & dementia (New York, N. Y.)

  5. Omega-3 fatty acids showed no clear effect on cognitive function in humans (healthy community-dwelling) (mean difference -0.01 standard units (95% CI: -0.02, 0.003; P = .15)).

    “We observed no significant effect of n-3 supplementation: the mean difference in annual rate of cognitive change for the n-3 versus placebo group was -0.01 standard units”

    Human trialhealthy community-dwelling1 g/day2 to 3 yearsn = 3,424

    Marine n-3 fatty acids and cognitive change among older adults in the VITAL randomized trial

    Alzheimer's & dementia (New York, N. Y.)

  6. Omega-3 fatty acids impair cognitive function in humans (high CAIDE score (i.e., ≥6)) (mean±SE = - 1.01±0.46).

    “There was significant less improvement (mean±SE = - 1.01±0.46) in the FCSRT free recall test in the n-3 PUFA intervention group compared to the placebo at 36 months.”

    Human trialhigh CAIDE score (i.e., ≥6)36 monthsn = 1,293

    Effects of a 3-Year Multi-Domain Intervention with or without Omega-3 Supplementation on Cognitive Functions in Older Subjects with Increased CAIDE Dementia Scores

    Journal of Alzheimer's disease : JAD

  7. Omega-3 fatty acids improve cognitive function in humans (mild cognitive impairment or dementia).

    “had the most significant effects on cognitive improvement, together with supplementation with omega-3 fatty acids (DHA and EPA).”

    Reviewmild cognitive impairment or dementiaDHA and EPA

    A scoping review of immunonutrients with antioxidant properties and their effect on mild cognitive impairment and dementia in the elderly

    Nutricion hospitalaria

  8. Omega-3 fatty acids improve cognitive function in humans (observational studies).

    “Observational studies generally associate higher dietary intake or circulating omega-3 status with better cognitive performance”

    Reviewobservational studies

    Food-Derived Omega-3 Fatty Acids and Cognitive Aging: Integrating Nutritional Neuroscience and Geroscience

    Nutrients

  9. Omega-3 fatty acids improve cognitive function in older adults.

    “Omega-3 supplementation has also been associated with improvements in inflammatory markers, cardiometabolic risk, cognitive function, and physical capacity in older adults.”

    Reviewin older adults

    Omega-3 fatty acids as modulators of advanced glycation end products in aging: mechanistic pathways and clinical implications - a narrative review

    Frontiers in aging

  10. Omega-3 fatty acids improve cognitive function in healthy older adults and patients with mild cognitive impairment.

    “supplementation, especially with DHA and EPA, acts through anti-inflammatory and antioxidant mechanisms, notably benefiting healthy older adults and patients with mild cognitive impairment.”

    Reviewin healthy older adults and patients with mild cognitive impairment

    Effect of omega-3 on cognitive function in adults with neurological impairment

    Tudo é Ciência.

All 23

C-reactive protein

downin humans8no changein humans4

12 studies
  1. Omega-3 fatty acids showed no clear effect on C-reactive protein in humans.

    “Neither was there any significant effect of ω-3 supplementation on lipid profiles or hs-CRP when compared with the placebo group.”

    Human trial8 weeksn = 40

    Influence of Fish Consumption and ω-3 Supplementation on the ω-3 Index of Young Adults: A 2 × 2 Factorial Randomized Controlled Trial (YouFish Study)

    The Journal of nutrition

  2. Omega-3 fatty acids showed no clear effect on C-reactive protein in patients with CKD undergoing hemodialysis (p = 0.716).

    “Comparing control versus supplemented groups after supplementation serum CRP levels have reduced, no differences were observed (p = 0.716)”

    Human trialin patients with CKD undergoing hemodialysiscapsules2g/day8 weeksn = 59

    Omega-3 supplementation effects on cardiovascular risk and inflammatory profile in chronic kidney disease patients in hemodialysis treatment: An intervention study

    Clinical nutrition ESPEN

  3. Omega-3 fatty acids decrease C-reactive protein in patients with lung cancer (1.42 ± 0.63 vs. 3.00 ± 1.05, p = 0.001).

    “Inflammatory markers were significantly reduced in omega-3 group compared to placebo (CRP 1.42 ± 0.63 vs. 3.00 ± 1.05, p = 0.001”

    Human trialin patients with lung cancerblood12 weeksn = 60

    Omega-3 Fatty Acids Supplementation Improve Nutritional Status and Inflammatory Response in Patients With Lung Cancer: A Randomized Clinical Trial

    Frontiers in nutrition

  4. Omega-3 fatty acids showed no clear effect on C-reactive protein in humans (moderate CKD).

    “Postintervention levels of IL-12, IL-18, and hsCRP were similar between the treatment groups.”

    Human trialmoderate CKD4 g daily8 weeksn = 73

    The Effects of OMEGA-3 Fatty Acid Supplementation Upon Interleukin-12 and Interleukin-18 in Chronic Kidney Disease Patients

    Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation

  5. Omega-3 fatty acids decrease C-reactive protein in humans.

    “Human clinical trials show that omega-3 supplementation reduces C-reactive protein (CRP), fibrinogen, and pro-inflammatory cytokines”

    Review

    Anti-inflammatory effects of omega-3 fatty acids: Evidence from circulating biomarkers and inflammatory gene-expression studies

    African Research Reports

  6. Omega-3 fatty acids decrease C-reactive protein in humans (HIV infection).

    “Omega-3 supplementation was associated with a consistent reduction in CRP”

    ReviewHIV infection

    Effect of omega-3 supplementation on metabolic and inflammatory markers in adults with HIV infection: a systematic review and meta-analysis

    Frontiers in nutrition

  7. Omega-3 fatty acids decrease C-reactive protein in humans across triglyceride formulations (SMD -0.62, 95 % CI -1.22 to -0.03).

    “Omega-3 fatty acids reduced CRP more than comparators across triglyceride formulations (SMD -0.62, 95 % CI -1.22 to -0.03; P = 0.04, I2 = 74 %)”

    Reviewacross triglyceride formulationstriglyceride formulationsn = 678

    Anti-inflammatory effects and safety of omega-3 fatty acids in haemodialysis: A systematic review and meta-analysis

    Clinical nutrition ESPEN

  8. Omega-3 fatty acids showed no clear effect on C-reactive protein in patients with heart failure (SMD: - 0.14, 95% CI: - 0.35-0.07).

    “no changes were observed in relation to CRP (k = 6; SMD: - 0.14, 95% CI: - 0.35-0.07, I2 = 0%, P = 0.20)”

    Reviewin patients with heart failure

    Does omega-3 supplementation improve the inflammatory profile of patients with heart failure? a systematic review and meta-analysis

    Heart failure reviews

  9. Omega-3 fatty acids decrease C-reactive protein in women with PCOS.

    “promising results were observed with different doses over 12 weeks of use, such as C-reactive protein (CRP) reduction”

    Reviewin women with PCOS12 weeks

    Omega-3 supplementation in the treatment of polycystic ovary syndrome (PCOS) - a review of clinical trials and cohort

    Endocrine regulations

  10. Omega-3 fatty acids decrease C-reactive protein in humans (patients on hemodialysis) (SMD -2.09 (95% CI -3.62, -0.56)).

    “and hs-CRP (SMD: -2.09; 95% CI: -3.62, -0.56)”

    Reviewpatients on hemodialysissupplementationn = 371

    The Effect of Omega-3 Supplementation on Serum Levels of Inflammatory Biomarkers and Albumin in Hemodialysis Patients: A Systematic Review and Meta-analysis

    Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation

All 13

More on C-reactive protein

Physical function

upin humans5no changein humans4upin reviews1

10 studies
  1. Omega-3 fatty acids showed no clear effect on physical function in humans (chronic inflammation).

    “individuals responded to these interventions metabolically despite null clinical outcomes.”

    Human trialchronic inflammation12 months

    Metabolomic Signatures of Physical Function and Functional Trajectories in Older Adults: Insights from the ENRGISE Clinical Trial

    Metabolites

  2. Omega-3 fatty acids improve physical function in humans (combined with resistance training).

    “For BP measurements, the group effect was p > 0.061, the effect of the time factor was p < 0.003, and the effect of the group × time interaction was p > 0.099.”

    Human trialcombined with resistance trainingeight consecutive weeksmalesn = 30

    The Effects of Omega-3 Supplementation Combined with Strength Training on Neuro-Biomarkers, Inflammatory and Antioxidant Responses, and the Lipid Profile in Physically Healthy Adults

    Nutrients

  3. Omega-3 fatty acids showed no clear effect on physical function in humans.

    “Neither supplemental vitamin D3 nor marine omega-3 fatty acids for 2 years improved physical performance in this generally healthy adult population.”

    Human trial1 g/day2 yearsn = 1,054

    Effects of Supplemental Vitamin D3, Omega-3 Fatty Acids on Physical Performance Measures in the VITamin D and OmegA-3 TriaL

    The Journal of clinical endocrinology and metabolism

  4. Omega-3 fatty acids showed no clear effect on physical function in humans.

    “treatment with vitamin D3, omega-3 fatty acids, or a strength training exercise program didn't result in clinically significant changes in blood pressure, nonvertebral fractures, physical performance, infection rates, or cognitive function”

    Human trial

    Dietary Supplements, Strength Training Offer no Significant Effects in Older Adults

    The American journal of nursing

  5. Omega-3 fatty acids showed no clear effect on physical function in humans (decreased muscle mass).

    “In our study, a 12 week supplementation of PUFA did not affect the evaluated parameters in elderly individuals with DMM.”

    Human trialdecreased muscle mass1.3 g PUFA and 10 mg vitamin E daily12 weeksn = 53

    The Effect of a 12-Week Omega-3 Supplementation on Body Composition, Muscle Strength and Physical Performance in Elderly Individuals with Decreased Muscle Mass

    International journal of environmental research and public health

  6. Omega-3 fatty acids improve physical function in humans (supplementation).

    “n-3 PUFA supplementation can improve muscle strength and physical performance in older adults”

    Reviewsupplementation

    n-3 Polyunsaturated Fatty Acids and Sarcopenia: Recent Advances and Mechanistic Research

    Nutrients

  7. Omega-3 fatty acids improve physical function in humans.

    “LCn-3 PUFA supplementation has been associated with improvements in muscle strength and physical function”

    Review

    The effect of long chain omega-3 polyunsaturated fatty acid supplementation on neuromuscular function in humans: a systematic review

    Preprint

  8. Omega-3 fatty acids improve physical function in humans (especially when combined with resistance training programs in the elderly).

    “many of them reported improved physical performance following supplementation, especially when combined with resistance training programs”

    Reviewespecially when combined with resistance training programs in the elderly

    Nutritional factors and physical frailty: Highlighting the role of functional nutrients in the prevention and treatment

    Ageing research reviews

  9. Omega-3 fatty acids improve physical function in humans.

    “these changes in MPS with chronic ո-3 PUFA ingestion have translated into clinically relevant improvements in muscle mass, strength and function”

    Reviewchronic

    Long-chain n-3 PUFA ingestion for the stimulation of muscle protein synthesis in healthy older adults

    The Proceedings of the Nutrition Society

  10. Omega-3 fatty acids improve physical function during aging.

    “increase the functional capacity of the muscle.”

    Reviewduring aging

    Regulation of Skeletal Muscle Satellite Cell Differentiation by Omega-3 Polyunsaturated Fatty Acids: A Critical Review

    Frontiers in physiology

Muscle mass

no changein humans4upin humans3upin reviews1

8 studies
  1. Omega-3 fatty acids showed no clear effect on muscle mass in humans (perioperative period of bariatric surgery) (p = 0.300).

    “Between baseline and 105 days, muscle mass decreased significantly in both groups (-3.1 ± 0.3 kg; -2.2 ± 0.5 kg; both p < 0.001), without interaction between groups (p = 0.300).”

    Human trialperioperative period of bariatric surgery2000 mg/day of EPA + DHA90 daysn = 58

    Effects of Omega-3 Supplementation in Sarcopenia After Bariatric Surgery: A Triple-Blind Randomized Controlled Clinical Trial

    Journal of cachexia, sarcopenia and muscle

  2. Omega-3 fatty acids increase muscle mass in humans.

    “There was a main effect of time with RET (P < 0.01 (Interaction: P = 0.69)), yet only the n-3 PUFA group significantly increased TFFM in the trained leg (3961 ± 151 g (P < 0.05, MD = +187, 95% CI = [20, 355], d = 0.91)), with no change in PLA (3561 ± 170 g (P = 0.08, MD = +154, 95% CI = [−13, 322], d = 0.55)) ( A”

    Human trial6 weeks

    Omega-3 supplementation during unilateral resistance exercise training in older women: A within subject and double-blind placebo-controlled trial

    Clinical nutrition ESPEN

  3. Omega-3 fatty acids increase muscle mass in humans with unilateral resistance exercise training (3774 ± 158 g to 3961 ± 151 g (P < 0.05) vs. 3406 ± 201 g to 3561 ± 170 PLA).

    “Only the n-3 PUFA group increased TFFM (3774 ± 158 g to 3961 ± 151 g n-3 PUFA (P < 0.05) vs. 3406 ± 201 g to 3561 ± 170 PLA)”

    Human trialwith unilateral resistance exercise trainingthigh3680 mg/day6 weeksfemalesn = 16

    Omega-3 supplementation during unilateral resistance exercise training in older women: A within subject and double-blind placebo-controlled trial

    Clinical nutrition ESPEN

  4. Omega-3 fatty acids showed no clear effect on muscle mass in humans (decreased muscle mass) (0.00 ± 0.30 kg/m2 in LMM-PUFA, 0.00 ± 0.22 kg/m2 in rLMM-PUFA).

    “No statistically significant differences were observed either in muscle mass or in the hand grip and TUG in any group.”

    Human trialdecreased muscle mass1.3 g PUFA and 10 mg vitamin E daily12 weeksn = 53

    The Effect of a 12-Week Omega-3 Supplementation on Body Composition, Muscle Strength and Physical Performance in Elderly Individuals with Decreased Muscle Mass

    International journal of environmental research and public health

  5. Omega-3 fatty acids were not clearly linked with muscle mass in humans.

    “The intake of omega-3 and its subtypes was not associated with muscle mass.”

    Humansfemalesn = 554

    Dietary omega-3 polyunsaturated fatty acid and alpha-linolenic acid are associated with physical capacity measure but not muscle mass in older women 65-72 years

    European journal of nutrition

  6. Omega-3 fatty acids increase muscle mass in humans (healthy).

    “LC n -3 PUFA supplementation increases muscle strength and mass in healthy older adults”

    Reviewhealthy

    Long-chain n-3 polyunsaturated fatty acid supplementation and neuromuscular function in older adults

    Current opinion in clinical nutrition and metabolic care

  7. Omega-3 fatty acids increase muscle mass in older adults.

    “Long-chain n-3 PUFA (LC n-3 PUFA) supplementation has been shown to enhance muscle protein synthesis rates, increase muscle mass and function”

    Reviewin older adults

    Nutrition strategies to counteract sarcopenia: a focus on protein, LC n-3 PUFA and precision nutrition

    The Proceedings of the Nutrition Society

  8. Omega-3 fatty acids showed no clear effect on muscle mass in humans (SMD = 0.07 [95% CI: -0.02, 0.17], P = 0.11).

    “n-3PUFA supplementation had no significant effect on muscle mass (standard mean difference [SMD] = 0.07 [95% CI: -0.02, 0.17], P = 0.11)”

    Reviewn = 1,443

    The Influence of n-3PUFA Supplementation on Muscle Strength, Mass, and Function: A Systematic Review and Meta-Analysis

    Advances in nutrition (Bethesda, Md.)

  9. Omega-3 fatty acids improve muscle mass during aging.

    “maintain muscle mass during aging, and increase the functional capacity of the muscle.”

    Reviewduring aging

    Regulation of Skeletal Muscle Satellite Cell Differentiation by Omega-3 Polyunsaturated Fatty Acids: A Critical Review

    Frontiers in physiology

Muscle strength

upin humans6no changein humans2

8 studies
  1. Omega-3 fatty acids showed no clear effect on muscle strength in humans (non-demented older adults) (between-group difference -0.05388 (-0.6800 to 0.5723, p = 0.8660)).

    “The between-group differences compared with placebo were -0.05388 (-0.6800 to 0.5723; Standard Error, SE = 0.3192; p = 0.8660) for the ω3-PUFA group”

    Human trialnon-demented older adults800 mg DHA and 225 mg EPA daily3 yearsn = 1,679

    Effect of Long-Term Omega 3 Polyunsaturated Fatty Acid Supplementation with or without Multidomain Lifestyle Intervention on Muscle Strength in Older Adults: Secondary Analysis of the Multidomain Alzheimer Preventive Trial (MAPT)

    Nutrients

  2. Omega-3 fatty acids showed no clear effect on muscle strength in humans (decreased muscle mass).

    “No statistically significant differences were observed either in muscle mass or in the hand grip and TUG in any group.”

    Human trialdecreased muscle mass1.3 g PUFA and 10 mg vitamin E daily12 weeksn = 53

    The Effect of a 12-Week Omega-3 Supplementation on Body Composition, Muscle Strength and Physical Performance in Elderly Individuals with Decreased Muscle Mass

    International journal of environmental research and public health

  3. Omega-3 fatty acids improve muscle strength in humans (supplementation).

    “n-3 PUFA supplementation can improve muscle strength and physical performance in older adults”

    Reviewsupplementation

    n-3 Polyunsaturated Fatty Acids and Sarcopenia: Recent Advances and Mechanistic Research

    Nutrients

  4. Omega-3 fatty acids improve muscle strength in humans (especially in long-duration interventions).

    “Most studies on omega-3 fatty acids reported improvements in muscle strength and functional outcomes, especially in long-duration interventions.”

    Reviewespecially in long-duration interventionsskeletal muscle

    The pivotal role of pro-anabolic modulators on muscle mass and function: a systematic review

    Nutrition research reviews

  5. Omega-3 fatty acids improve muscle strength in humans.

    “LCn-3 PUFA supplementation has been associated with improvements in muscle strength and physical function”

    Review

    The effect of long chain omega-3 polyunsaturated fatty acid supplementation on neuromuscular function in humans: a systematic review

    Preprint

  6. Omega-3 fatty acids improve muscle strength in humans (healthy).

    “LC n -3 PUFA supplementation increases muscle strength and mass in healthy older adults”

    Reviewhealthy

    Long-chain n-3 polyunsaturated fatty acid supplementation and neuromuscular function in older adults

    Current opinion in clinical nutrition and metabolic care

  7. Omega-3 fatty acids improve muscle strength in healthy and clinical older adult populations.

    “Systematic reviews and meta-analyses of randomized controlled trials consistently report small, but clinically-relevant, effects of LC n -3 PUFA ingestion on strength outcomes”

    Reviewin healthy and clinical older adult populations

    Long-chain n -3 polyunsaturated fatty acids for the management of age- and disease-related declines in skeletal muscle mass, strength and physical function

    Current opinion in clinical nutrition and metabolic care

  8. Omega-3 fatty acids improve muscle strength in humans (SMD = 0.12 [95% CI: 0.006, 0.24], P = 0.04).

    “it showed a very small albeit significant positive effect on muscle strength (SMD = 0.12 [95% CI: 0.006, 0.24], P = 0.04) in participants when compared with placebo.”

    Reviewn = 1,443

    The Influence of n-3PUFA Supplementation on Muscle Strength, Mass, and Function: A Systematic Review and Meta-Analysis

    Advances in nutrition (Bethesda, Md.)

IL-6

downin humans6no changein humans1−14%

7 studies
  1. Omega-3 fatty acids decrease IL-6 in humans during the Trier Social Stress Test (2.5 g/d group had 33% lower IL-6 geometric mean than placebo).

    “Omega-3 also reduced overall cortisol (p = 0.03) and IL-6 (p = 0.03) throughout the stressor”

    Human trialduring the Trier Social Stress Test2.5 g/d4 monthsn = 138

    Omega-3 supplementation and stress reactivity of cellular aging biomarkers: an ancillary substudy of a randomized, controlled trial in midlife adults

    Molecular psychiatry

  2. Omega-3 fatty acids decrease IL-6 in humans.

    “Omega-3 supplementation did not affect IL-6 stress reactivity (interaction effect p=0.11), but it did lower overall IL-6 levels (main effect F(2, 226)=3.73, p=0.03).”

    Human trialn = 131

    Omega-3 supplementation and stress reactivity of cellular aging biomarkers: an ancillary substudy of a randomized, controlled trial in midlife adults

    Molecular psychiatry

  3. Omega-3 fatty acids decrease IL-6 in humans (compared with standard formula without ω-3) (5.7 vs 6.3 pg/mL).

    “as was a reduction of interleukin-6 (5.7 [4.1-6.4] versus 6.3 pg/mL [5.6-8.6]; P = 0.03)”

    Human trialcompared with standard formula without ω-3formula enriched with ω-330 d

    Effects of ω-3 supplementation on the nutritional status, immune, and inflammatory profiles of gastric cancer patients: A randomized controlled trial

    Nutrition (Burbank, Los Angeles County, Calif.)

  4. Omega-3 fatty acids decrease IL-6 in humans (-0.19 pg/ml).

    “The following compounds showed a significant small to large effect in reducing IL-6 levels: probiotics (-0.68 pg/ml), ARBs (-0.37 pg/ml) and omega-3 (-0.19 pg/ml).”

    Human trial

    Evidence-based nutritional and pharmacological interventions targeting chronic low-grade inflammation in middle-age and older adults: A systematic review and meta-analysis

    Ageing research reviews

  5. Omega-3 fatty acids decrease IL-6 in humans (-14%).

    “The estimated mean stimulated log-IL-6 value was 0.15 units lower in the supplemented group than the placebo group, corresponding to 14% decrease in the geometric mean of IL-6 (p=.04).”

    Human trialcapsules12 weeksn = 68

    Omega-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial

    Brain, behavior, and immunity

  6. Omega-3 fatty acids decrease IL-6 in humans (added to structured exercise versus exercise alone) (MD −0.77 pg/mL; 95% CI −1.46 to −0.08).

    “post-intervention IL-6 was lower by 0.77 pg/mL when omega-3 supplementation was added to exercise versus exercise alone”

    Reviewadded to structured exercise versus exercise alone8–18 weeks

    Does omega-3 supplementation added to exercise attenuate inflammaging? Effects on circulating interleukin-6 in older adults: A meta-analysis of randomized controlled trials

    Physical Therapy Journal of Indonesia

  7. Omega-3 fatty acids decrease IL-6 in patients with heart failure (SMD: - 1.27, 95% CI: - 1.88- - 0.66).

    “IL-6 levels (k = 4; SMD: - 1.27, 95% CI: - 1.88- - 0.66, I2 = 81%, P < 0.0001) compared to placebo”

    Reviewin patients with heart failure

    Does omega-3 supplementation improve the inflammatory profile of patients with heart failure? a systematic review and meta-analysis

    Heart failure reviews

  8. Omega-3 fatty acids showed no clear effect on IL-6 in patients with digestive system cancer.

    “variations in the IL-6 and CRP concentrations in patients with digestive system cancer did not differ between the supplementation groups and the controls”

    Reviewin patients with digestive system cancer

    Associations between Omega-3 Fatty Acid Supplementation and Anti-Inflammatory Effects in Patients with Digestive System Cancer: A Meta-Analysis

    Nutrition and cancer

More on IL-6

Mortality

downin humans4no changein humans3HR 0.15–0.96

7 studies
  1. Omega-3 fatty acids decrease mortality in humans (posterior HRs 0.91–0.92).

    “Without skepticism into the priors, ranges of posterior HRs for total CVD, cardiovascular death and all-cause death were 0.95–0.96, 0.91–0.92 and 0.95–0.96, respectively.”

    Human trialmedian of 5.3 years (range, 3.8 to 6.1)n = 25,871

    A Bayesian analysis of the VITAL trial: effects of ω-3 fatty acid supplementation on cardiovascular events

    The American journal of clinical nutrition

  2. Omega-3 fatty acids decrease mortality in humans (posterior HR 0.95-0.96).

    “Without skepticism into the priors, posterior HRs were 0.95-0.96 in CVD, 0.91-0.92 in cardiovascular death, and 0.95-0.96 in all-cause death risks, respectively.”

    Human trial1.2:1840 mg/d5.3 yn = 25,871

    A Bayesian analysis of the VITAL trial: effects of ω-3 fatty acid supplementation on cardiovascular events

    The American journal of clinical nutrition

  3. Omega-3 fatty acids are linked with lower mortality in humans.

    “SHAP analysis revealed that intake of magnesium and n-3 fatty acid were associated with reduced risk of both advanced CKM stages and all-cause mortality.”

    Humansn = 7,918

    Association of dietary quality, biological aging, progression and mortality of cardiovascular-kidney-metabolic syndrome: insights from mediation and machine learning approaches

    Nutrition journal

  4. Omega-3 fatty acids are linked with lower mortality in humans (post-myocardial infarction) (HR 0.15, 95% CI 0.05-0.46).

    “associated with a further and complementary reduction in all-cause mortality (HR 0.15, 95% CI 0.05-0.46)”

    Humanspost-myocardial infarction

    Omega-3 fatty acid supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction

    European journal of clinical pharmacology

  5. Omega-3 fatty acids decrease mortality in humans (higher dose or highly purified esters).

    “reduction in cardiovascular death and incidence of cardiovascular disease”

    Reviewhigher dose or highly purified esters

    Current Evidence and Future Directions of Omega-3 Supplementation and Cardiovascular Disease Risk

    The International journal of angiology : official publication of the International College of Angiology, Inc

  6. Omega-3 fatty acids showed no clear effect on mortality in humans (≤1 capsule/day).

    “Omega-3 supplementation as ≤1 capsule/day was not associated with any outcome under study”

    Review≤1 capsule/day≤1 capsule/day

    Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis

    Heart (British Cardiac Society)

  7. Omega-3 fatty acids showed no clear effect on mortality in humans (acute myocardial infarction) (RR 1.06, 95% CI 0.90 to 1.27).

    “Omega 3 fatty acids probably make little or no difference to all-cause mortality (4 studies 9141 patients RR 1.06 - CI95% 0.90 to 1.27, moderate certainty)”

    Reviewacute myocardial infarctionn = 9,141

    Omega 3 fatty acid supplementation after myocardial infarction: a systematic review and meta-analysis

    BMC cardiovascular disorders

  8. Omega-3 fatty acids showed no clear effect on mortality in humans (RR, 0.96; 95% CI, 0.91 to 1.02).

    “No statistically significant association was observed with all-cause mortality (RR, 0.96; 95% CI, 0.91 to 1.02”

    Review

    Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis

    JAMA

Cardiovascular disease

no changein humans4downin humans2HR 0.92

6 studies
  1. Omega-3 fatty acids showed no clear effect on cardiovascular disease in humans (aHR = 1.00, 95% CI 0.64–1.56).

    “Based on the main effects analysis, we did not find any statistically significant benefit of any of the three interventions with regard to the risk of MACE: omega-3 versus no omega-3 (adjusted hazard ratio (aHR) = 1.00, 95% CI 0.64–1.56), nor vitamin D3 versus no vitamin D3 (aHR = 1.37, 95% CI 0.88–2.14), SHEP versus control exercise (aHR = 1.18, 95% CI 0.76–1.84”

    Human trialthree yearsn = 2,089

    Effects of vitamin D, omega-3 and a simple strength exercise programme in cardiovascular disease prevention: The DO-HEALTH randomized controlled trial

    The journal of nutrition, health & aging

  2. Omega-3 fatty acids showed no clear effect on cardiovascular disease in humans (adjustedHR 1.00, 95%CI 0.64-1.56).

    “neither omega-3 (adjustedHR 1.00, 95%CI 0.64-1.56), nor vitamin D3 (aHR 1.37, 95%CI 0.88-2.14), nor SHEP (aHR 1.18, 95%CI 0.76-1.84) reduced risk of MACE”

    Human trial3 years

    Effects of vitamin D, omega-3 and a simple strength exercise programme in cardiovascular disease prevention: The DO-HEALTH randomized controlled trial

    The journal of nutrition, health & aging

  3. Omega-3 fatty acids showed no clear effect on cardiovascular disease in humans (reciprocal win ratio 0.90, 95% CI 0.78 to 1.04, p = 0.15).

    “The total numbers of winners and losers were 5,000,010 and 4,510,845, respectively, in the n−3 fatty acid vs. placebo groups, resulting in slightly but not significantly reduced reciprocal win ratios (95% CI) of 0.90 (0.78 to 1.04; p = 0.15) in all participants.”

    Human trialmedian follow-up period of 5.3 years (ranging from 3.8 to 6.1 years)n = 25,871

    Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease: A Novel Analysis of the VITAL Trial Using Win Ratio and Hierarchical Composite Outcomes

    Nutrients

  4. Omega-3 fatty acids showed no clear effect on cardiovascular disease in humans.

    “The VITAL and STRENGTH trials failed to demonstrate significant cardiovascular benefit with omega-3 supplementation”

    Review

    Oxidative Stress in Vascular Aging: Therapeutic Potential of the Antioxidant Paradox. A State-of-the-Art Review

    Antioxidants (Basel, Switzerland)

  5. Omega-3 fatty acids protect against cardiovascular disease in humans.

    “synthesize the clinical evidence supporting omega-3 supplementation in cardiovascular protection, neuroprotection, and the mitigation of autoimmune and metabolic dysregulation”

    Review

    FISH OIL AND OMEGA-3 FATTY ACIDS IN CHRONIC DISEASES: PREVENTIVE AND THERAPEUTIC PERSPECTIVES

    PARIPEX-INDIAN JOURNAL OF RESEARCH

  6. Omega-3 fatty acids showed no clear effect on cardiovascular disease in humans (general population unselected for elevated cardiovascular risk) (HR = 0.92 (95% confidence interval 0.80-1.06)).

    “Compared with an olive oil placebo, the n-3 FA intervention did not significantly reduce the primary endpoint of major CVD events”

    Reviewgeneral population unselected for elevated cardiovascular risk1.2:1 ratio of eicosapentaenoic to docosahexaenoic acid1 g/daymedian of 5.3 yearsn = 25,871

    Marine omega-3 fatty acid supplementation and prevention of cardiovascular disease: update on the randomized trial evidence

    Cardiovascular research

  7. Omega-3 fatty acids protect against cardiovascular disease in humans.

    “The hypolipemic, anti-inflammatory, anti-arrhythmic properties of these fatty acids confer cardioprotection.”

    Review

    Omega-3 fatty acid supplementation and cardiovascular disease

    Journal of lipid research

More on Cardiovascular disease

Telomere length

no changein humans2upin reviews2upin humans1upin mice1

6 studies
  1. Omega-3 fatty acids showed no clear effect on telomere length in humans.

    “Marine n-3 FAs supplementation had no significant effect on LTL at either year 2 or year 4.”

    Human trialleukocyte1 g/day4 yearsn = 1,031

    Vitamin D₃ and marine ω-3 fatty acids supplementation and leukocyte telomere length: 4-year findings from the VITamin D and OmegA-3 TriaL (VITAL) randomized controlled trial

    The American journal of clinical nutrition

  2. Omega-3 fatty acids increase telomere length.

    “Evidence supporting that n-3 PUFAs might have beneficial effects on maintaining telomere length reinforce the salutary effects of these dietary fats.”

    Review

    Fatty acids and telomere length

    Current opinion in clinical nutrition and metabolic care

  3. Omega-3 fatty acids increase telomere length in mice (relative LTL: WT = 1.00 ± 0.09 vs. fat-1: 1.25 ± 0.05, P = 0.031; absolute LTL: WT = 64.41 ± 6.50 vs. fat-1: 78.53 ± 3.86, P = 0.048).

    “In animals aged 10 months, the LTL was significantly longer in fat-1 than in WT mice”

    Animalsblood

    Elevated tissue status of omega-3 fatty acids protects against age-related telomere attrition in fat-1 transgenic mice

    Clinical nutrition (Edinburgh, Scotland)

  4. Omega-3 fatty acids improve telomere length.

    “the vast majority indicate a beneficial effect of omega-3 fatty acids on telomere length”

    Review

    Effect of Omega-3 Fatty Acids on Telomeres-Are They the Elixir of Youth?

    Nutrients

  5. Omega-3 fatty acids showed no clear effect on telomere length in humans.

    “Omega-3 PUFA supplementation did not statistically affect telomere length in three out of three studies”

    Review

    Effect of omega-3 fatty acid supplementation on telomere length and telomerase activity: A systematic review of clinical trials

    Prostaglandins, leukotrienes, and essential fatty acids

  6. Omega-3 fatty acids increase telomere length in humans (mean difference = 0.16; 95% CI, 0.02, 0.30; p = 0.02).

    “results revealed an overall beneficial effect of omega-3 fatty acids on the telomere length (mean difference = 0.16; 95% CI, 0.02, 0.30; p = 0.02)”

    Reviewn = 337

    Effect of omega-3 fatty acids on the telomere length: A mini meta-analysis of clinical trials

    Biomolecular concepts

More on Telomere length

Omega-3 index

upin humans4no changein humans1

4 studies
  1. Omega-3 fatty acids increase omega-3 index in humans.

    “For the second principal comparison, ω-3 supplementation compared with placebo, similar results were observed. Ω-3 supplementation resulted in significant increases in the O3I and erythrocyte concentrations of EPA and total n–3 PUFAs when compared with those in the placebo group (all FDR P < 0.05).”

    Human trial8 weeksn = 40

    Influence of Fish Consumption and ω-3 Supplementation on the ω-3 Index of Young Adults: A 2 × 2 Factorial Randomized Controlled Trial (YouFish Study)

    The Journal of nutrition

  2. Omega-3 fatty acids increase omega-3 index in humans (healthy adults with low-fish intake and O3I <6%) (+2.03% ± 0.88%).

    “Consumption of 2 portions of fish/week and ω-3 supplementation resulted in a significant mean % increase in O3I of 2.27% ± 0.82% and 2.03% ± 0.88%, respectively.”

    Human trialhealthy adults with low-fish intake and O3I <6%700 mg EPA+DHA supplement capsule daily8-wkn = 40

    Influence of Fish Consumption and ω-3 Supplementation on the ω-3 Index of Young Adults: A 2 × 2 Factorial Randomized Controlled Trial (YouFish Study)

    The Journal of nutrition

  3. Omega-3 fatty acids showed no clear effect on omega-3 index in humans.

    “showing a significant increase in both study groups but no significant differences between the groups at the end of the intervention”

    Human trialfour-monthn = 82

    FADS1 Genetic Variant and Omega-3 Supplementation Are Associated with Changes in Fatty Acid Composition in Red Blood Cells of Subjects with Obesity

    Nutrients

  4. Omega-3 fatty acids increase omega-3 index in both groups.

    “The n-3 index (O3I) increased at the end of the intervention in both groups.”

    Human trialin both groupsred blood cellsfour monthsn = 76

    FADS1 Genetic Variant and Omega-3 Supplementation Are Associated with Changes in Fatty Acid Composition in Red Blood Cells of Subjects with Obesity

    Nutrients

  5. Omega-3 fatty acids increase omega-3 index in humans.

    “The post intervention ω-3 index was significantly higher and AA/EPA significantly lower in the ω-3 PUFA compared to the placebo group (p < 0.01, p < 0.05, respectively).”

    Human trialthree weeksmalesn = 24

    The Effect of Omega-3 Fatty Acid Supplementation on Serum Adipocytokines, Lipid Profile and Biochemical Markers of Inflammation in Recreational Runners

    Nutrients

  6. Omega-3 fatty acids increase omega-3 index in humans (compared to pre-supplementation levels) (p < 0.001).

    “A significantly higher ω-3 index and lower AA/EPA ratio was observed after ω-3 PUFA compared to pre-supplementation levels (p < 0.001 and p < 0.001, respectively).”

    Human trialcompared to pre-supplementation levels3 weeksn = 24

    The Effect of Omega-3 Fatty Acid Supplementation on Serum Adipocytokines, Lipid Profile and Biochemical Markers of Inflammation in Recreational Runners

    Nutrients

  7. Omega-3 fatty acids increase omega-3 index in humans.

    “Omega-3 index increased significantly in the LC-n3-FA group compared with the placebo group.”

    Human trial2,200 mg/day26 weeksn = 44

    Impact of Omega-3 Fatty Acid Supplementation on Memory Functions in Healthy Older Adults

    Journal of Alzheimer's disease : JAD

More on Omega-3 index

Autoimmune disease

downin humans2no changein humans1downin mice1HR 0.85

4 studies
  1. Omega-3 fatty acids showed no clear effect on autoimmune disease in humans (0.85, 0.67 to 1.08).

    “For the omega 3 fatty acid group, confirmed autoimmune disease occurred in 130 participants in the treatment group and 148 in the placebo group (0.85, 0.67 to 1.08, P=0.19; ).”

    Human trialfive yearsn = 25,871

    Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial

    BMJ (Clinical research ed.)

  2. Omega-3 fatty acids showed no clear effect on autoimmune disease in humans (HR 0.85, 95% CI 0.67 to 1.08).

    “In the omega 3 fatty acids arm, 130 participants in the treatment group and 148 in the placebo group had a confirmed autoimmune disease (0.85, 0.67 to 1.08, P=0.19).”

    Human trial1000 mg/daymedian of 5.3 yearsn = 25,871

    Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial

    BMJ (Clinical research ed.)

  3. Omega-3 fatty acids protect against autoimmune disease in humans.

    “synthesize the clinical evidence supporting omega-3 supplementation in cardiovascular protection, neuroprotection, and the mitigation of autoimmune and metabolic dysregulation”

    Review

    FISH OIL AND OMEGA-3 FATTY ACIDS IN CHRONIC DISEASES: PREVENTIVE AND THERAPEUTIC PERSPECTIVES

    PARIPEX-INDIAN JOURNAL OF RESEARCH

  4. Omega-3 fatty acids decrease autoimmune disease in humans.

    “Omega-3 fatty acid supplementation is associated with a significant reduction in disease activity in several autoimmune diseases”

    Review

    Modulation of inflammation and immunity by omega-3 fatty acids: a possible role for prevention and to halt disease progression in autoimmune, viral, and age-related disorders

    European review for medical and pharmacological sciences

  5. Omega-3 fatty acids decrease autoimmune disease in lupus-prone (NZB x NZW)F1 mice.

    “both FR and omega-3 (n-3) fatty acids diet lowered the severity of autoimmune disease both in lupus-prone (NZB x NZW)F1 mice”

    Reviewin lupus-prone (NZB x NZW)F1 mice

    Modulation of gene expression in autoimmune disease and aging by food restriction and dietary lipids

    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)

More on Autoimmune disease

Oxidative stress and ROS signaling

downin humans2no changein humans1downin reviews1

4 studies
  1. Omega-3 fatty acids decrease oxidative stress and ROS signaling in humans (combined with resistance training).

    “For malondialdehyde measurements, the group effect was p > 0.210, the effect of the time factor was p < 0.005, and the effect of the group × time interaction was p > 0.091.”

    Human trialcombined with resistance trainingeight consecutive weeksmalesn = 30

    The Effects of Omega-3 Supplementation Combined with Strength Training on Neuro-Biomarkers, Inflammatory and Antioxidant Responses, and the Lipid Profile in Physically Healthy Adults

    Nutrients

  2. Omega-3 fatty acids showed no clear effect on oxidative stress and ROS signaling in hemodialysis patients.

    “Supplementation was not able to alter lipid or OS profiles.”

    Human trialin hemodialysis patients1.28 g/day12 weeksn = 88

    Omega-3 Fatty Acid Supplementation is Associated With Oxidative Stress and Dyslipidemia, but Does not Contribute to Better Lipid and Oxidative Status on Hemodialysis Patients

    Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation

  3. Omega-3 fatty acids decrease oxidative stress and ROS signaling in humans (older adults).

    “n3-PUFA did not change respiration, but significantly reduced oxidant emissions.”

    Human trialolder adultsskeletal muscle3.9g/day16 weeksn = 12

    Influence of omega-3 fatty acids on skeletal muscle protein metabolism and mitochondrial bioenergetics in older adults

    Aging

  4. Omega-3 fatty acids decrease oxidative stress and ROS signaling in preclinical models.

    “Preclinical evidence demonstrates that omega-3 PUFAs attenuate oxidative stress and inflammatory signalling, partly through RAGE axis regulation and PPARγ activation.”

    Reviewin preclinical models

    Omega-3 fatty acids as modulators of advanced glycation end products in aging: mechanistic pathways and clinical implications - a narrative review

    Frontiers in aging

More on Oxidative stress and ROS signaling

Lipid profile

upin humans1no changein humans1upin rats1upin reviews1

4 studies
  1. Omega-3 fatty acids improve lipid profile in humans.

    “ANOVA revealed a significant effect of ω-3 PUFA on serum HDL-C levels (F = 11.1 p < 0.01).”

    Human trialthree weeksmalesn = 24

    The Effect of Omega-3 Fatty Acid Supplementation on Serum Adipocytokines, Lipid Profile and Biochemical Markers of Inflammation in Recreational Runners

    Nutrients

  2. Omega-3 fatty acids showed no clear effect on lipid profile in hemodialysis patients.

    “Supplementation was not able to alter lipid or OS profiles.”

    Human trialin hemodialysis patients1.28 g/day12 weeksn = 88

    Omega-3 Fatty Acid Supplementation is Associated With Oxidative Stress and Dyslipidemia, but Does not Contribute to Better Lipid and Oxidative Status on Hemodialysis Patients

    Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation

  3. Omega-3 fatty acids improve lipid profile.

    “Omega-3 fatty acids modulate microbiome composition and improve lipid profiles.”

    Review

    Age Versus Immunity: Dietary Influences on Immunosenescence

    Journal of clinical medicine

  4. Omega-3 fatty acids improve lipid profile in naturally aged rats.

    “in omega-3 fats alone consumed rats the lipid profile was improved”

    Animalsin naturally aged rats

    Vitamin E supplementation modulates the biological effects of omega-3 fatty acids in naturally aged rats

    Toxicology mechanisms and methods

More on Lipid profile

All 303

What is omega-3 fatty acids linked with?

81

Studies link omega-3 fatty acids with 81 measures, most often myocardial infarction (7 studies), cardiovascular disease (6) and coronary artery disease (5).

Myocardial infarction

downin humans7HR 0.72–0.9

7 studies
  1. Omega-3 fatty acids lower the risk of myocardial infarction in humans (primary prevention) (HR 0.72, 95% CI 0.59–0.90).

    “did significantly reduce total myocardial infarction (MI; HR=0.72 [0.59-0.90])”

    Human trialprimary prevention1 g/daymedian of 5.3 yearsn = 25,871

    Omega-3s did not significantly cut major cardiovascular events

    The Journal of nutrition

  2. Omega-3 fatty acids lower the risk of myocardial infarction in humans.

    “Effects of omega-3 FA supplementation on CHD and total MI were robust across the priors, with the posterior HR estimates varying from 0.88 – 0.93 and 0.82 – 0.90, respectively.”

    Human trialmedian of 5.3 years (range, 3.8 to 6.1)n = 25,871

    A Bayesian analysis of the VITAL trial: effects of ω-3 fatty acid supplementation on cardiovascular events

    The American journal of clinical nutrition

  3. Omega-3 fatty acids lower the risk of myocardial infarction in humans (posterior HR 0.82 to 0.90).

    “and 0.82 to 0.90, respectively.”

    Human trial1.2:1840 mg/d5.3 yn = 25,871

    A Bayesian analysis of the VITAL trial: effects of ω-3 fatty acid supplementation on cardiovascular events

    The American journal of clinical nutrition

  4. Omega-3 fatty acids lower the risk of myocardial infarction in humans (reciprocal win ratio 0.71, 95% CI 0.57 to 0.88, p = 0.002).

    “However, we obtained significant reciprocal win ratios (95% CI) of 0.71 (0.57 to 0.88; p = 0.002) and 0.83 (0.71 to 0.96; p = 0.01), respectively, for the hierarchical composite outcomes of MI and CHD events, showing significant benefits of the n−3 fatty acid supplementation for these two outcomes.”

    Human trialmedian follow-up period of 5.3 years (ranging from 3.8 to 6.1 years)n = 25,871

    Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease: A Novel Analysis of the VITAL Trial Using Win Ratio and Hierarchical Composite Outcomes

    Nutrients

  5. Omega-3 fatty acids lower the risk of myocardial infarction in humans (0.71, 95% CI 0.57-0.88).

    “Its benefits came from reducing MI (0.71 [0.57-0.88]) but not stroke (1.01 [0.80 to 1.28]) components.”

    Human trial1 g/dayn = 25,871

    Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease: A Novel Analysis of the VITAL Trial Using Win Ratio and Hierarchical Composite Outcomes

    Nutrients

  6. Omega-3 fatty acids are linked with a lower risk of myocardial infarction in African Americans (OR 0.17, 95% CI [0.048, 0.60]).

    “n-3 supplementation significantly lowered MI risk in AfAm (OR 0.17, 95% CI [0.048, 0.60]), with no such effect in NHW.”

    Humansin African Americans

    Optimal Pair Matching Combined with Machine Learning Predicts a Significant Reduction in Myocardial Infarction Risk in African Americans Following Omega-3 Fatty Acid Supplementation

    Nutrients

  7. Omega-3 fatty acids lower the risk of myocardial infarction in humans (general population unselected for elevated cardiovascular risk) (HR = 0.72 (0.59-0.90)).

    “did significantly reduce total MI [HR = 0.72 (0.59-0.90)]”

    Reviewgeneral population unselected for elevated cardiovascular risk1.2:1 ratio of eicosapentaenoic to docosahexaenoic acid1 g/daymedian of 5.3 yearsn = 25,871

    Marine omega-3 fatty acid supplementation and prevention of cardiovascular disease: update on the randomized trial evidence

    Cardiovascular research

  8. Omega-3 fatty acids lower the risk of myocardial infarction in humans.

    “MI (RR; 0.86; CI: 0.79-0.93; p for heterogeneity 0.28; I 2 = 19%; p < 0.01)”

    Review

    Omega-3 Fatty Acid Supplementation and Coronary Heart Disease Risks: A Meta-Analysis of Randomized Controlled Clinical Trials

    Frontiers in nutrition

  9. Omega-3 fatty acids lower the risk of myocardial infarction in humans (RR 0.92, 95% CI 0.86-0.99).

    “marine omega-3 supplementation was associated with significantly lower risk of myocardial infarction (rate ratio [RR] [95% CI]: 0.92 [0.86, 0.99]; P=0.020)”

    Review5.0 years

    Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127 477 Participants

    Journal of the American Heart Association

More on Myocardial infarction

Cardiovascular disease

downin humans6RR 0.92–0.93

6 studies
  1. Omega-3 fatty acids lower the risk of cardiovascular disease in humans (low fish consumption at baseline) (0.79, 95% CI 0.65-0.96).

    “participants with low fish consumption at baseline benefited (0.79 [0.65-0.96]) more than those with high consumption (1.05 [0.85-1.30])”

    Human triallow fish consumption at baseline1 g/dayn = 25,871

    Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease: A Novel Analysis of the VITAL Trial Using Win Ratio and Hierarchical Composite Outcomes

    Nutrients

  2. Omega-3 fatty acids are associated with cardiovascular disease in humans.

    “Age-standardized death and DALYs rates for CVD attributable to low seafood n-3 polyunsaturated fatty acids (PUFAs) and high trans fatty acids declined”

    Humans

    Burden of cardiovascular disease in China attributable to unbalanced fatty acid intake from 1990 to 2050

    Asia Pacific journal of clinical nutrition

  3. Omega-3 fatty acids lower the risk of cardiovascular disease in humans.

    “Evidence from clinical and epidemiological studies supports the health benefits of Omega-3 fortification, including reduced risk of cardiovascular diseases”

    Review

    Fortification of Omega-3 Fatty Acids in Food Products: Advancements, Methods, Benefits, and Consumer Acceptance - A Comprehensive Review

    International Journal for Research in Applied Science and Engineering Technology

  4. Omega-3 fatty acids lower the risk of cardiovascular disease in humans (higher dose or highly purified esters).

    “reduction in cardiovascular death and incidence of cardiovascular disease”

    Reviewhigher dose or highly purified esters

    Current Evidence and Future Directions of Omega-3 Supplementation and Cardiovascular Disease Risk

    The International journal of angiology : official publication of the International College of Angiology, Inc

  5. Omega-3 fatty acids lower the risk of cardiovascular disease in humans (RR 0.92, 95% CI 0.86–0.97; absolute risk reduction 1.48%).

    “The meta-analysis determined a significant reduction in omega-3 in CVD (RR = 0.92, 95% CI: 0.86~0.97) and ARR (1.48%).”

    Reviewsupplements

    Assessing Health and Economic Benefits of Omega-3 Fatty Acid Supplementation on Cardiovascular Disease in the Republic of Korea

    Healthcare (Basel, Switzerland)

  6. Omega-3 fatty acids lower the risk of cardiovascular disease in humans (RR 0.93, 95% CI 0.88-0.99).

    “CVD death (RR [95% CI]: 0.93 [0.88, 0.99]; P=0.013)”

    Review5.0 years

    Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127 477 Participants

    Journal of the American Heart Association

More on Cardiovascular disease

Coronary artery disease

downin humans4downin reviews1HR 0.88–0.93

5 studies
  1. Omega-3 fatty acids lower the risk of coronary artery disease in humans (absolute risk difference of −0.47% (95% CI: −0.84, −0.10)).

    “On average, omega-3 FA supplementation reduced the 5-year CHD risk, with an absolute risk difference of −0.47% (95% CI: −0.84, −0.10).”

    Human trialalmost 5 yearsn = 25,871

    Identification of individuals who benefit from omega-3 fatty acid supplementation to prevent coronary heart disease: a machine-learning analysis of the VITAL

    European journal of epidemiology

  2. Omega-3 fatty acids lower the risk of coronary artery disease in humans (top tertile of the expected benefit) (1.21% absolute risk reduction vs 0.47% average).

    “there was 1.21% absolute CHD risk reduction in the top tertile of the expected benefit, compared with the average effect of 0.47% risk reduction.”

    Human trialtop tertile of the expected benefit5-yearn = 25,871

    Identification of individuals who benefit from omega-3 fatty acid supplementation to prevent coronary heart disease: a machine-learning analysis of the VITAL

    European journal of epidemiology

  3. Omega-3 fatty acids lower the risk of coronary artery disease in humans.

    “According to primary informed priors, probabilities of omega-3 FA being effective versus placebo (i.e. posterior HR < 1) were 99.7% for CHD, 99.6% for total MI, 98.4% for CVD, 98.8% for all-cause death, 99.8% for cardiovascular death, and 33.7% for stroke, respectively.”

    Human trial1 g per daymedian of 5.3 years (range, 3.8 to 6.1)n = 25,871

    A Bayesian analysis of the VITAL trial: effects of ω-3 fatty acid supplementation on cardiovascular events

    The American journal of clinical nutrition

  4. Omega-3 fatty acids lower the risk of coronary artery disease in humans (posterior HR 0.88 to 0.93).

    “The effects of ω-3 FA supplementation on CAD and MI were robust across the priors, with the posterior HR estimates varying from 0.88 to 0.93”

    Human trial1.2:1840 mg/d5.3 yn = 25,871

    A Bayesian analysis of the VITAL trial: effects of ω-3 fatty acid supplementation on cardiovascular events

    The American journal of clinical nutrition

  5. Omega-3 fatty acids lower the risk of coronary artery disease (dose-dependent reduction).

    “Omega-3 supplementation reduces coronary heart disease and myocardial infarction risk dose-dependently”

    Reviewdose-dependent reduction

    Diet and Risk of Cardiovascular Disease

    The American journal of medicine

  6. Omega-3 fatty acids lower the risk of coronary artery disease in humans.

    “omega-3 supplementation significantly decreased the risks of coronary heart disease and myocardial infarction only, in the comparison with the control group”

    Review

    Comparative Effect of Statins and Omega-3 Supplementation on Cardiovascular Events: Meta-Analysis and Network Meta-Analysis of 63 Randomized Controlled Trials Including 264,516 Participants

    Nutrients

  7. Omega-3 fatty acids lower the risk of coronary artery disease in humans (RR 0.92, 95% CI 0.86-0.98).

    “CHD death (RR [95% CI]: 0.92 [0.86, 0.98]; P=0.014)”

    Review5.0 years

    Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127 477 Participants

    Journal of the American Heart Association

More on Coronary artery disease

Cognitive function

upin humans3mixedin humans1mixedin reviews1

5 studies
  1. Omega-3 fatty acids are associated with cognitive function in humans (p = 0.012).

    “higher cognition levels (p = 0.012)”

    Humans

    Dietary n-3 Polyunsaturated Fatty Acids From Fish Are Associated With Better Healthy Aging Indicators: Results of the DIAPELH Study

    Journal of human nutrition and dietetics : the official journal of the British Dietetic Association

  2. Omega-3 fatty acids are associated with cognitive function in humans (beta 0.53, 95% CI: 0.33-0.72, P < 0.0001).

    “the beta coefficients for the CERAD Word Learning test, Animal Fluency Test, and Digit Symbol Substitution Test were 0.53 (95% CI: 0.33-0.72, P < 0.0001)”

    Humansn = 2,430

    Dietary omega-3 intake and cognitive function in older adults

    International journal of psychiatry in medicine

  3. Omega-3 fatty acids are associated with cognitive function in humans (β: 0.41; 95% CI: 0.03, 0.78).

    “Mixture analysis showed significant positive associations with DSST scores for fish consumption (β: 0.88; 95% CI: 0.48, 1.29) and dietary ω-3 PUFAs (β: 0.41; 95% CI: 0.03, 0.78)”

    Humansn = 3,123

    Fish consumption and omega-3 polyunsaturated fatty acids from diet are positively associated with cognitive function in older adults even in the presence of exposure to lead, cadmium, selenium, and methylmercury: a cross-sectional study using NHANES 2011-2014 data

    The American journal of clinical nutrition

  4. Omega-3 fatty acids are associated with cognitive function in humans (P for non-linearity = 0.01, P for dose-response = 0.005).

    “Levels of episodic memory decreased with the increase in omega-3 dose and then appeared to increase with an upward curve (P for non-linearity = 0.01, P for dose-response = 0.005).”

    Review

    A systematic review and dose response meta analysis of Omega 3 supplementation on cognitive function

    Scientific reports

  5. Omega-3 fatty acids are associated with cognitive function.

    “influencing feeding behavior, neural plasticity, and memory during aging”

    Review

    Fatty Acids, Antioxidants and Physical Activity in Brain Aging

    Nutrients

Alzheimer's disease

downin humans5OR 0.36

5 studies
  1. Omega-3 fatty acids are associated with Alzheimer's disease in humans (Adjusted for potential confounders) (OR 0.36, 95% CI 0.18–0.74; 64% lower odds).

    “individuals in the third tertile of total dietary omega-3 fatty acids had 64 percent lower chance of Alzheimer's disease”

    HumansAdjusted for potential confoundersthird tertile of total dietary omega-3 fatty acidsn = 301

    Unravelling the link between dietary omega-3 fatty acids and risk of Alzheimer's disease: a case-control study

    Nutritional neuroscience

  2. Omega-3 fatty acids are associated with Alzheimer's disease in humans (Highest versus lowest quintile of total omega-3 status) (Q5 vs. Q1: HR 0.87, 95% CI 0.76–1.00).

    “the total omega-3 status was inversely related to the risk of Alzheimer's”

    HumansHighest versus lowest quintile of total omega-3 statusn = 267,312

    Plasma Omega-3 Fatty Acids and Risk for Incident Dementia in the UK Biobank Study: A Closer Look

    Nutrients

  3. Omega-3 fatty acids are linked with a lower risk of Alzheimer's disease in humans (APOE ε4 carriers; long-term use).

    “Long-term ω-3 use protected cognition (especially memory function) and lowered amyloid burden and AD risk only amongst APOE ε4 carriers.”

    HumansAPOE ε4 carriers; long-term uselong-term

    A gene-environment interplay between omega-3 supplementation and APOE ε4 provides insights for Alzheimer's disease precise prevention amongst high-genetic-risk population

    European journal of neurology

  4. Omega-3 fatty acids are associated with Alzheimer's disease in humans.

    “The available data suggests that food items rich in antioxidants, omega-3 fatty acids, and B vitamins are associated with a lower risk of developing Alzheimer's disease.”

    Review

    Exploring the Role of Nutrition in Supporting Brain Health and Reducing the Risk of Alzheimer's Disease

    Current Alzheimer research

  5. Omega-3 fatty acids lower the risk of Alzheimer's disease in humans (epidemiology cohorts).

    “Epidemiology cohorts reveal associations between levels or intake of omega-3 polyunsaturated fatty acids (n-3 PUFA) and a lower risk of Alzheimer's disease (AD).”

    Reviewepidemiology cohorts

    Designing Newer Omega-3 Supplementation Trials for Cognitive Outcomes: A Systematic Review Guided Analysis

    Journal of Alzheimer's disease : JAD

More on Alzheimer's disease

Age-related macular degeneration

downin humans5HR 0.8

5 studies
  1. Omega-3 fatty acids are linked with a lower risk of age-related macular degeneration in humans (HR 0.80, 95% CI 0.72-0.95).

    “Higher plasma levels (in millimoles per liter) of omega-3 (hazard ratio [HR], 0.80; 95% confidence interval [CI], 0.72-0.95; P = 0.006) and DHA (HR, 0.65; 95% CI, 0.44-0.96; P = 0.029) were associated with lower risk of receiving an AMD diagnosis.”

    Humansplasma12.9 years

    Omega-3 Fatty Acids as Protective Factors for Age-Related Macular Degeneration: Prospective Cohort and Mendelian Randomization Analyses

    Ophthalmology

  2. Omega-3 fatty acids are linked with a lower risk of age-related macular degeneration in humans (early AMD) (RR 0.86, 95% CI 0.77-0.96).

    “Higher dietary intakes of omega-3 PUFA was significantly associated with 14% (relative risk [RR]: 0.86, 95% confidence interval [CI]: 0.77, 0.96) and 29% (RR: 0.71, 95% CI: 0.55, 0.91) lower risk of early and late AMD, respectively.”

    Humansearly AMD

    Dietary omega-3 polyunsaturated fatty acids and fish intake and risk of age-related macular degeneration

    Clinical nutrition (Edinburgh, Scotland)

  3. Omega-3 fatty acids lower the risk of age-related macular degeneration in humans (OR 0.67, 95% CI 0.51-0.88).

    “A high intake of omega-3 LCPUFAs (OR:0.67; 95%CI:[0.51, 0.88]; p = 0.004)”

    Review

    Association between fatty acid intake and age-related macular degeneration: a meta-analysis

    Frontiers in nutrition

  4. Omega-3 fatty acids lower the risk of age-related macular degeneration in humans (ES 0.51, 95% CI 0.34-0.75, p = 0.01).

    “people with high dietary long-chain omega-3 polyunsaturated fatty acids (omega-3 LCPUFAs) have a lower risk of progression to advanced age-related macular degeneration (AMD) (effect size, ES: 0.51, 95 % CI [0.34, 0.75]”

    Review

    Dietary omega-3 LCPUFA intake in the prevention of neovascular age-related macular degeneration: a systematic review and meta-analysis

    Nutricion hospitalaria

  5. Omega-3 fatty acids lower the risk of age-related macular degeneration in humans.

    “regular consumption of foods that contain ω-3 fatty acids is associated with a lower risk for late AMD”

    Review

    Association of Nutrients, Specific Dietary Patterns, and Probiotics with Age-related Macular Degeneration

    Current medicinal chemistry

More on Age-related macular degeneration

Atrial fibrillation

upin humans2downin humans1upin reviews1HR 0.19

4 studies
  1. Omega-3 fatty acids are linked with a lower risk of atrial fibrillation in humans (post-myocardial infarction) (HR 0.19, 95% CI 0.07-0.51).

    “N-3 PUFA reduced the relative risk of the hospitalization for AF [hazard ratio (HR) 0.19, 95% CI 0.07-0.51]”

    Humanspost-myocardial infarction1-year

    Omega-3 fatty acid supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction

    European journal of clinical pharmacology

  2. Omega-3 fatty acids raise the risk of atrial fibrillation.

    “High-dose ω-3 formulations, regardless of EPA monotherapy or EPA/DHA combination, carry a dose-dependent atrial fibrillation risk that warrants age-stratified assessment.”

    ReviewEPA monotherapy or EPA/DHA combinationhigh-dose

    Natural Fish Oil Versus Purified Fish Oil: Composition, Efficacy, and Applications

    Journal of nutrition and metabolism

  3. Omega-3 fatty acids raise the risk of atrial fibrillation in humans (high-dose supplementation).

    “high-dose supplementation has also been linked to a modestly increased risk of atrial fibrillation”

    Reviewhigh-dose supplementation

    Fatty Acids and Their Roles in Cardiac Physiology and Pathology: Mechanistic and Interventional Studies

    Preprints.orgPreprint

  4. Omega-3 fatty acids raise the risk of atrial fibrillation in heart-healthy older adults.

    “in heart-healthy older adults, it may increase the risk of atrial fibrillation and stroke.”

    Reviewin heart-healthy older adults

    Revisiting the Omega-3 Paradox in Cardiovascular Prevention: A Precision Medicine Perspective within the discipline of Mind-Body-Medicine

    THE MIND - Bulletin on Mind-Body Medicine Research

More on Atrial fibrillation

Dementia

downin humans3HR 0.79

3 studies
  1. Omega-3 fatty acids are associated with dementia in humans (HR 0.79, 95% CI 0.63–0.99; nominally significant).

    “Omega-3 level and reduced risk of PD (HR = 0.67, P = 0.03, 95 % CI = 0.46-0.97) and dementia”

    HumansserumMean follow-up of 13.3 years

    Association of Omega-3 and Omega-6 with neurodegenerative disorders: a UK biobank prospective cohort study

    Parkinsonism & related disorders

  2. Omega-3 fatty acids are linked with a lower risk of dementia in humans.

    “certain medication combinations, such as omega-3 fatty acids and multivitamins, were inversely associated with dementia and mortality”

    Humansup to 15 yearsn = 361,970

    Polypharmacy and its association with dementia, Parkinson's disease, and mortality risk in UK adults: a multistate modeling approach

    GeroScience

  3. Omega-3 fatty acids lower the risk of dementia in humans (observational studies).

    “Observational studies generally associate higher dietary intake or circulating omega-3 status with better cognitive performance and a lower risk of cognitive decline and dementia.”

    Reviewobservational studies

    Food-Derived Omega-3 Fatty Acids and Cognitive Aging: Integrating Nutritional Neuroscience and Geroscience

    Nutrients

More on Dementia

Mortality

downin humans3HR 0.75–0.94

3 studies
  1. Omega-3 fatty acids are linked with a lower risk of mortality in humans (HR 0.94, 95% CI 0.89-0.99).

    “each additional gram per day of omega-3 PUFA intake was associated with a 6% reduction in mortality risk (HR: 0.94, 95% CI: 0.89-0.99).”

    Humanseach additional gram per day

    Higher dietary omega-3 polyunsaturated fatty acid intake is associated with reduced all-cause mortality in cancer survivors: A prospective cohort study

    Nutrition research (New York, N.Y.)

  2. Omega-3 fatty acids are linked with a lower risk of mortality in humans (highest versus lowest intake quartile) (HR 0.75, 95% CI 0.61-0.92).

    “Participants in the highest versus lowest intake quartile had 48% lower odds of severe CKM stage (OR, 0.52 [95% CI, 0.46-0.60]) and 25% lower mortality (HR, 0.75 [95% CI, 0.61-0.92]).”

    Humanshighest versus lowest intake quartile

    Association of Higher Dietary Omega-3 Fatty Acid Intake With Cardiovascular-Kidney-Metabolic Syndrome Stage Severity and Mortality in US Adults: A Cross-Sectional and Prospective Cohort Analysis of NHANES 1999 to 2018

    Journal of the American Heart Association

  3. Omega-3 fatty acids are linked with a lower risk of mortality in humans (depression) (HR 0.76 (95% CI: 0.62, 0.94)).

    “The HRs for the highest versus lowest quartile of omega-3 PUFAs were 0.76 (95% CI: 0.62, 0.94) for total mortality”

    Humansdepressionn = 6,782

    Omega-3 polyunsaturated fatty acids and mortality risk in depression: immune-inflammatory mediation in NHANES 1999-2018

    Nutrition journal

Cardiovascular mortality

downin humans2HR 0.72

2 studies
  1. Omega-3 fatty acids are linked with a lower risk of cardiovascular mortality in humans (depression) (HR 0.72 (95% CI: 0.50, 1.02)).

    “0.72 (95% CI: 0.50, 1.02) for CVD mortality”

    Humansdepressionn = 6,782

    Omega-3 polyunsaturated fatty acids and mortality risk in depression: immune-inflammatory mediation in NHANES 1999-2018

    Nutrition journal

  2. Omega-3 fatty acids lower the risk of cardiovascular mortality in humans.

    “n--3 long chain PUFAs such as eicosapentaenoic acid and docosahexaenoic acid have been associated with reduced cardiovascular mortality”

    Review

    Fatty Acids and Their Roles in Cardiac Physiology and Pathology: Mechanistic and Interventional Studies

    Preprints.orgPreprint

Autoimmune disease

downin humans1HR 0.82

1 study
  1. Omega-3 fatty acids lower the risk of autoimmune disease in humans (confirmed plus probable cases) (HR 0.82, 95% CI 0.68–0.99).

    “was associated with significantly decreased risk of autoimmune disease (confirmed plus probable cases; HR=0.82 [0.68-0.99])”

    Human trialconfirmed plus probable cases1 g/daymedian of 5.3 years

    Omega-3s did not significantly cut major cardiovascular events

    The Journal of nutrition

More on Autoimmune disease

LDL-C

downin humans1

1 study
  1. Omega-3 fatty acids are associated with LDL-C in humans (pesco-vegetarian diet).

    “the level of omega-3 fatty acid intake was correlated to the reduction of blood low-density lipoprotein cholesterol and total cholesterol.”

    Human trialpesco-vegetarian dietblood1 week

    Dietary intake and blood biomarker changes with a one-week pesco-vegetarian diet intervention supplemented with varying dose of ginger and curcumin: A single-blinded randomized clinical trial

    Nutrition and health

More on LDL-C

Functional connectivity

mixedin humans1

1 study
  1. Omega-3 fatty acids are associated with functional connectivity in humans (interaction with baseline CDR status).

    “This shows that the observed effect between intervention groups and baseline CDR status is driven by omega-3 fatty acid supplementation.”

    Human trialinteraction with baseline CDR status36 monthsn = 100

    Impact of multidomain preventive strategies on functional brain connectivity in older adults with cognitive complaint: Subset from the Montpellier center of the ancillary MAPT-MRI study

    Frontiers in aging neuroscience

Functional connectivity

mixedin humans1

1 study
  1. Omega-3 fatty acids are associated with functional connectivity in humans (dependent on cognitive decline status).

    “an effect of omega-3 fatty acid supplementation dependent on cognitive decline status was underlined for frontoparietal, salience, visual and sensorimotor networks FC.”

    Human trialdependent on cognitive decline status36 monthsn = 100

    Impact of multidomain preventive strategies on functional brain connectivity in older adults with cognitive complaint: Subset from the Montpellier center of the ancillary MAPT-MRI study

    Frontiers in aging neuroscience

More on Functional connectivity

Trail-making test A score

downin humans1

1 study
  1. Omega-3 fatty acids are associated with trail-making test A score in humans (baseline plasma homocysteine <= 16.8 umol/L) (Estimate: -1.3, 95% CI: -2.3; -0.3, p=0.01).

    “We found a significant association between TMT-A and red blood cell n-3 PUFA levels in participants with Hcy values ≤16.8 μMol/L after adjustments at baseline (Estimate: -1.3, 95% CI: -2.3; -0.3, p=0.01).”

    Human trialbaseline plasma homocysteine <= 16.8 umol/L

    Omega-3 Supplementation for the Prevention of Cognitive Decline in Older Adults: Does It Depend on Homocysteine Levels?

    The journal of nutrition, health & aging

All 81

What acts on omega-3 fatty acids?

1

Studies name omega-6 fatty acids as acting on omega-3 fatty acids.

Omega-6 fatty acids

downin reviews1

1 study
  1. Omega-6 fatty acids inhibit omega-3 fatty acids.

    “Diets rich in ω-6 fatty acids inhibit the formation of healthier ω-3 fatty acids.”

    Review

    Mediterranean diet: The role of long-chain ω-3 fatty acids in fish; polyphenols in fruits, vegetables, cereals, coffee, tea, cacao and wine; probiotics and vitamins in prevention of stroke, age-related cognitive decline, and Alzheimer disease

    Revue neurologique

More on Omega-6 fatty acids

Has omega-3 fatty acids been tested in people?

11 of 22 about aging

Yes: 298 trials and 109 observational studies in people have been published.

Funding

11 grants since 2018

National Heart, Lung, and Blood Institute$2.1MNational Institute of Diabetes and Digestive and Kidney Diseases$1.3MJapan Society for the Promotion of Science¥8.8M

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Animal studies report lifespan extension in mice but shortening in rats. Independent labs report reduced triglycerides and inflammation and improved cognition in humans, alongside null inflammation and cognition results; a human trial reports lower epigenetic aging measures but another reports no effect on frailty. Two registered trials concern aging; most trials across uses have company sponsors, and papers declare company ties.

  2. Summary rewritten as its findings changed.

    As it read before

    A human observational study links higher omega-3 intake to lower mortality; independent labs report lower human inflammation and triglycerides. Lifespan increases in tau-transgenic mice contrast with decreases in rats; some human inflammation studies report no effect. Two findings have company-affiliated authors, and three papers declare company ties.

  3. Summary rewritten as its findings changed.

    As it read before

    Reviews reach conflicting conclusions on cardiovascular health, describing lower coronary heart disease risk alongside an increased risk of atrial fibrillation with high-dose formulations in high-risk populations, whereas another review reports no effect on human cardiovascular disease.

  4. Summary written from the findings.

Latest

Dec 2025: 18Jan 2026: 25Feb 2026: 19Mar 2026: 31Apr 2026: 16May 2026: 11Jun 2026: 11Jul 2026: 17Aug 2026: 14Sep 2026: 12Oct 2026: 20Nov 2026: 10204 papers in 12 months
The Journal of Nutrition

Omega-3s did not significantly cut major cardiovascular events

Major cardiovascular events had a hazard ratio of 0.92 versus placebo, with 1 meaning no difference; heart attacks were less frequent.Major cardiovascular events had a hazard ratio of 0.92 versus placebo, with 1 meaning no difference; heart attacks were less frequent.

Randomized trial · 25,871 peopleCardiovascular disease

See all 731 papers on omega-3 fatty acids